GRI Bio, Inc. (GRI) AI Stock Analysis

Headquartered in La Jolla, California, GRI Bio, Inc. is a clinical-stage biopharmaceutical firm dedicated to treating inflammatory, fibrotic, and autoimmune diseases across the United States. Founded in 2009 as Glycoregimmune, Inc., the company focuses on advancing therapeutic innovations. Its clinical pipeline includes GRI-0621, which is in phase II clinical development for idiopathic pulmonary fibrosis, and GRI-0803, currently undergoing phase I trials for systematic lupus erythematosus. In pre-clinical stages, the firm is developing GRI-0124 for primary sclerosing cholangitis alongside GRI-0729. GRI Bio is also working on ADAIR and ADMIR therapies for attention-deficit/hyperactivity disorder.

Annual revenue rose from $100,000 in FY2020 to $21.8M in FY2023, before increasing 3.5% to $22.5M in FY2024. Gross margin came in at -0.0% in FY2024, improving from -0.3% in FY2023 and 100.0% in FY2020. Operating margin improved to -36.5% in FY2024 compared to -52.3% in FY2023 and -1459.0% in FY2020. Net income was -$8.2M in FY2024, following losses of -$13.0M in FY2023 and -$2.5M in FY2020, yielding an EPS of -$334.28. Research and development expenses reached $3.8M in FY2024. Over the trailing twelve months ending June 30, 2026, revenue was $0, with an operating margin of 0.0% and an EPS of -$14.71.

As of June 30, 2026, GRI Bio held $10.9M in cash and short-term investments alongside $44,000 in total debt, resulting in net cash of $10.9M. The current ratio stood at 10.30 and the debt-to-equity ratio was 0.00, supported by shareholders' equity of $10.3M and total assets of $11.4M. Operating cash flow was -$8.6M in FY2024, matching free cash flow of -$8.6M. Capital allocation in FY2025 included $3,000 in capital expenditures and $1,000 directed to share buybacks.

At the last close of $1.38 on October 16, 2026, GRI Bio carries a market capitalization of $3.0M and an enterprise value of -$6.3M. Its price-to-book ratio is 0.5x. By comparison, the median of its US-listed Healthcare peers trades at a price-to-sales multiple of 4.1x, an EV/EBITDA ratio of 12.0x, and maintains an operating margin of 14.0%. Over the past year, GRI fell 97.5% while the S&P 500 gained 16.8%. Over a five-year horizon, the stock dropped 100.0%, lagging the S&P 500 return of 83.0%.

Consensus coverage consists of 2 Strong Buy ratings, with 0 Buy, Hold, Sell, or Strong Sell recommendations. The mean price target is $18.50, reflecting a premium of 1240.6% over the last close of $1.38. For the fiscal year ending December 31, 2026, analysts estimate an EPS of -$3.90, representing projected EPS growth of 96.8% on expected revenue of $0. For the following fiscal year, analysts forecast an EPS of -$2.00 on $0 in revenue. GRI beat EPS estimates in 2 of the past 4 quarters, and its next earnings date is November 13, 2026.

This page is an AI-written research summary of GRI Bio, Inc. (GRI). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: GRI income statement, GRI balance sheet, GRI key metrics, GRI analyst forecast, GRI chart. See the GRI stock overview for the latest quote and news.